These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4014106)

  • 41. Evidence for an erythropoietin-stimulating factor in patients with renal and hepatic disease.
    Naughton BA; Liu P; Naughton GK; Gordon AS
    Acta Haematol; 1983; 69(3):171-9. PubMed ID: 6404100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma protein binding of etomidate in patients with renal failure or hepatic cirrhosis.
    Carlos R; Calvo R; Erill S
    Clin Pharmacokinet; 1979; 4(2):144-8. PubMed ID: 455872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Radioimmunoassay for dexamethasone and its plasma levels after oral administration in patients with liver disease].
    Murakami M; Miyachi Y; Nanno M; Yoshimi T
    Nihon Naibunpi Gakkai Zasshi; 1990 Aug; 66(8):760-9. PubMed ID: 2209923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased acetylation of isoniazid in chronic renal failure.
    Kim YG; Shin JG; Shin SG; Jang IJ; Kim S; Lee JS; Han JS; Cha YN
    Clin Pharmacol Ther; 1993 Dec; 54(6):612-20. PubMed ID: 8275616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Zinc deficiency and the severity of hepatic cirrhosis].
    Ortuño JA; Garrido G; Cubillo P; Alfonso V; Aznar J; Berenguer J
    Med Clin (Barc); 1987 Jun; 89(3):99-103. PubMed ID: 3626657
    [No Abstract]   [Full Text] [Related]  

  • 46. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 47. Phenylbutazone protein binding in normal subjects and hypoproteinemic patients.
    Kshirsagar NA; Pahujani SM; Paul T; Sheth UK
    Indian J Med Res; 1979 Dec; 70():1006-9. PubMed ID: 540998
    [No Abstract]   [Full Text] [Related]  

  • 48. Glutathione kinetics in normal man and in patients with liver cirrhosis.
    Bianchi G; Bugianesi E; Ronchi M; Fabbri A; Zoli M; Marchesini G
    J Hepatol; 1997 Mar; 26(3):606-13. PubMed ID: 9075668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of disease and acetazolamide on procaine hydrolysis by red blood cell enzymes.
    Calvo R; Carlos R; Erill S
    Clin Pharmacol Ther; 1980 Feb; 27(2):179-83. PubMed ID: 7353336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
    Thomson PD; Melmon KL; Richardson JA; Cohn K; Steinbrunn W; Cudihee R; Rowland M
    Ann Intern Med; 1973 Apr; 78(4):499-508. PubMed ID: 4694036
    [No Abstract]   [Full Text] [Related]  

  • 51. Factors affecting plasma clearance of (14C) cholic acid in patients with cirrhosis.
    Kaye MD; Struthers JE; Tidball JS; DeNiro E; Kern F
    Clin Sci Mol Med; 1973 Aug; 45(2):147-61. PubMed ID: 4522356
    [No Abstract]   [Full Text] [Related]  

  • 52. Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease.
    Ghoneim MM; Kramer E; Bannow R; Pandya H; Routh JI
    Anesthesiology; 1973 Oct; 39(4):410-5. PubMed ID: 4758349
    [No Abstract]   [Full Text] [Related]  

  • 53. Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver.
    Cameron DP; Burger HG; Catt KJ; Gordon E; Watts JM
    Metabolism; 1972 Oct; 21(10):895-904. PubMed ID: 5071956
    [No Abstract]   [Full Text] [Related]  

  • 54. Cholecystokinin octapeptide and bulimia nervosa.
    Arnold CB
    Am J Psychiatry; 1994 Jul; 151(7):1098. PubMed ID: 8010376
    [No Abstract]   [Full Text] [Related]  

  • 55. Enzymatic synthesis of cholecystokinin-octapeptide.
    Sakina K; Kawazura K; Morihara K; Yajima H
    Chem Pharm Bull (Tokyo); 1988 Oct; 36(10):3915-9. PubMed ID: 3245972
    [No Abstract]   [Full Text] [Related]  

  • 56. Cholecystokinin and cystic fibrosis.
    Jansen JB; Jongerius CM; Lamers CB
    Lancet; 1985 Jan; 1(8419):58. PubMed ID: 2856992
    [No Abstract]   [Full Text] [Related]  

  • 57. Case of Hepatic Cirrhosis Eight and a Half Years after the Disappearance of Ascites.
    Weber FP
    Proc R Soc Med; 1924; 17(Clin Sect):25-8. PubMed ID: 19983517
    [No Abstract]   [Full Text] [Related]  

  • 58. Pancreatic trophism in experimental liver cirrhosis.
    Nagy I; Hajnal F; Mohácsi G; Németh J; Lászik Z; Pap A
    Int J Pancreatol; 1993 Oct; 14(2):157-66. PubMed ID: 8283079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis.
    Pompili M; Rapaccini GL; Caturelli E; Curró D; Montuschi P; D'Amato M; Aliotta A; Grattagliano A; Cedrone A; Anti M
    Dig Dis Sci; 1995 Feb; 40(2):428-34. PubMed ID: 7851211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inactivation of cholecystokinin octapeptide by normal and cirrhotic liver in rats.
    Berger Z; Pap A; Ungi I; Varró V
    Int J Pancreatol; 1986 Oct; 1(3-4):279-89. PubMed ID: 3681028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.